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Background: Treating prostate cancer with SBRT could potentially minimize radiation proctitis by reducing
high-dose rectal irradiation. In addition, it offers the potential radiobiologic benefits of hypofractionation. This study
reports the endoscopic changes and the associated clinical rectal toxicity in these patients.
Methods: We reviewed the records of patients treated from 2008–2011 for localized prostate cancer who had
rectal endoscopy following SBRT. SBRT was delivered either as primary treatment in 5 fractions of 7–7.25 Gy, or as
an initial boost in 3 fractions of 6.5 Gy followed by conventionally fractionated radiotherapy to 45–50.4 Gy.
Endoscopic changes were graded using the Vienna Rectoscopy Score (VRS). Rectal toxicity was graded via
CTCAEv.4. Rectal quality of life (QOL) was assessed via the bowel domain of the EPIC-26 questionnaire.
Results: Fifty-one patients with a median 23 months follow-up were analyzed. Thirty-five patients completed SBRT
monotherapy and 16 patients received SBRT as a boost to conventionally fractionated IMRT. The median interval from
SBRT to rectal endoscopy was 13 months. Endoscopy revealed VRS Grade 1–2 telangiectasias for 10 patients and VRS
Grade 1–2 mucosal edema for 12 patients. No rectal ulcerations, strictures or necrosis were observed. Grade 1–2 late
rectal bleeding occurred in 10 patients. There were no CTCAEv.4 Grade ≥3 toxicities. Mean EPIC bowel scores
decreased from a baseline value of 96.9 to 82.3 at 1-month, but subsequently increased to 91.0 at 24 months.
Conclusions: In this cohort that is skewed towards patients with rectal complaints, the rate and severity of endoscopic
changes following SBRT is low. Rectal toxicity and QOL were comparable to patients treated with other radiation
modalities. Prospective trials examining the endoscopic outcomes following SBRT for prostate cancer are needed for
confirmation of the findings of this study.
Trial registration: The Georgetown Institutional Review Board has approved this retrospective study (IRB 2009–510).
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toxicity, Quality of lifeBackground
Radiation therapy is a well-established treatment modal-
ity for clinically localized prostate cancer. Late radiation
proctitis occurs at a frequency of 5–20% when radiother-
apy is delivered with conventional radiation therapy for
localized prostate cancer [1]. Patients with radiation-* Correspondence: SPC9@gunet.georgetown.edu
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reproduction in any medium, provided the orinduced proctopathy describe symptoms of rectal pain,
bowel frequency/urgency and rectal bleeding. These symp-
toms occur months to years after treatment (average 8–
12 months), with the large majority of patients reporting
symptoms within two years following pelvic radiation
therapy [2,3]. Patient characteristics such as a history of
hemorrhoids, inflammatory bowel disease [4] or antico-
agulation therapy [5] may increase an individual patient’s
risk for clinically significant proctopathy. Endoscopic find-
ings in patients with clinical proctopathy include telan-
giectasia, congested mucosa, and ulcers. Rectal bleedingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of patients receiving conventionally fractionated radiation
therapy [6]. These rectal complications are the principle
dose-limiting toxicities of radiotherapy. Several trials have
demonstrated an improved biochemical failure-free sur-
vival with dose-escalation, but the increased rates of rectal
toxicities are a potential barrier to the use of escalated
doses [7-9].
The risk of proctitis and rectal bleeding appeared to be
dependent upon both the total radiation dose and the vol-
ume of the rectum in the high dose area [10]. Treatment-
related factors such as prostate motion and radiation
schedules can contribute substantially to the severity of
rectal toxicities. The prostate gland has been shown to
move both interfractionally and intrafractionally during
the delivery of external-beam radiotherapy [11]. As a re-
sult, a 0.5-1.5 cm margin is usually added to the clinical
target volume (CTV) in generating the planning treatment
volume (PTV) to account for this motion with conven-
tional radiotherapy or intensity-modulated radiotherapy
(IMRT). The need for such margins limits the ability to
escalate dose to the prostate and spare normal tissues.
The optimal radiation schedule for the curative treat-
ment of prostate cancer remains unknown. Recent data
suggest that large radiation fraction sizes are radiobio-
logically favorable over lower fraction sizes in prostate
cancer [12-14]. The α/β for prostate cancer may be as
low as 1.5 Gy, [14] as opposed to values of 6–8 Gy re-
ported for other adenocarcinomas [12]. If the α/β for
prostate adenocarcinoma is less than the value of 3 Gy
that is generally accepted for late rectal complications,
the linear-quadratic model predicts a greater therapeutic
gain for hypofractionated radiotherapy over convention-
ally fractionated treatment regimens. High dose-rate
(HDR) brachytherapy using 6–9.5 Gy per fraction has
been shown to be safe and effective in the treatment of
localized prostate cancer [15-17]. The use of large fraction
sizes in SBRT offers the potential radiobiologic benefits
of hypofractionation with the minimal invasiveness of an
external-beam treatment modality.
Stereotactic body radiation therapy (SBRT) offers to
minimize radiation-associated rectal toxicity by reduc-
ing the volume of rectum receiving high radiation doses.
The CyberKnife robotic radiosurgical system uses image
guidance to track implanted fiducials to account for
intrafraction prostatic motion [18]. This decreases the
uncertainty of the location of the prostate and allows
treatment to be delivered with a smaller CTV to PTV
expansion, which reduces the doses delivered to the rec-
tum. Early results from our center [19] and others [20-22]
suggest a similar efficacy as alternative radiation modalities
with low rates of late Grade ≥2 rectal toxicity (< 10%). The
goal of this study is to report the endoscopic findings fol-
lowing SBRT for clinically localized prostate cancer andcorrelate these outcomes with clinical rectal toxicity and
quality of life.Methods
Patients treated at our institution with SBRT for clinically
localized prostate cancer who underwent at least one post-
treatment rectal endoscopy were identified and included in
this retrospective review. Clinical stage was defined ac-
cording to the 6th edition of the American Joint Committee
on Cancer criteria. Risk groups were defined using the Na-
tional Comprehensive Cancer Network (NCCN) criteria.
Institutional review board approval was obtained for this
review.
SBRT was delivered using the CyberKnife robotic ra-
diosurgical system. The fiducial placement and CT/MRI
simulation procedures have been previously described in
Lei et al. [23]. The clinical target volume (CTV) was de-
fined as the prostatic capsule and proximal seminal vesi-
cles (SV) up to the point that the SVs split, and included
gross extracapsular extension or SV involvement seen on
MRI. The expansion from the CTV to the planning target
volume (PTV) was 5 mm in all directions except 3 mm
posteriorly into the rectum. Fiducial-based tracking was
used to account for intrafraction and interfraction prostate
motion. Treatment planning was performed using Multi-
plan (Accuray Inc., Sunnyvale, CA). Patients with low-risk
prostate cancer and select patients with intermediate-risk
cancer were treated with 35 or 36.25 Gy of radiotherapy de-
livered in 5 fractions of 7–7.25 Gy each to the PTV [21,24].
Patients with high-risk prostate cancer and most patients
with intermediate-risk cancer were treated with 19.5 Gy
of radiotherapy delivered in 3 fractions of 6.5 Gy each as
a boost, followed by 45–50.4 Gy of intensity-modulated
radiotherapy (IMRT) delivered in 1.8 Gy daily fractions
[25]. The dose constraints to the rectum for SBRT have
been previously described [24,25]. An example of the dose
distributions from an SBRT monotherapy plan is shown in
Figure 1. Patients were placed on a low-residual diet and
given enemas prior to simulation and treatment delivery to
maximize the potential distance between the prostate and
the rectal wall and minimize intrafraction prostate motion.
Endoscopic proctopathy was graded and scored using the
Vienna Rectoscopy Score (VRS) [26]. For VRS telangiecta-
sia grading, a single telangiectasia is Grade 1, multiple non-
confluent telangiectasia Grade 2, and multiple confluent
telangiectasia Grade 3. For VRS congested mucosa grading,
focal reddening of the mucosa combined with edematous
mucosa is Grade 1, diffuse non-confluent reddening of the
mucosa combined with edematous mucosa Grade 2, and
diffuse confluent reddening of the mucosa combined with
edematous mucosa Grade 3. If a patient had more than 1
endoscopy in the follow-up period, the worst endoscopic
findings seen between all studies were recorded.
Figure 1 Treatment planning scan. Axial (A) and sagittal (B)
computed tomography images the prostate GTV (red line), bladder
(orange line) and rectum (yellow demonstrating line). Isodose lines
shown as follows: 100% of the prescription dose (lavender line); 90%
of the prescription dose (yellow line); 75% of the prescription dose
(green line); 50% of the prescription dose (brown line).
Table 1 Patient characteristics (n = 51)
Characteristic Median (range)
Age 67 (range 52–83)
Length of clinical follow-up (months) 23 (range 8–47)








Pre-SBRT use of anticoagulation therapy 11 (22%)
Pre-SBRT hemorrhoids 4 (8%)
Radiotherapy
SBRT monotherapy 35 (69%)



















≤ 10 ng/mL 41 (80%)
> 10 ng/mL 10 (20%)
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each visit via CTCAE v.4. Clinical acute toxicities were
defined as an increase of symptoms over the patient’s pre-
treatment baseline at any follow up visit prior to or at
6 months and late toxicities were defined as those that
occur after 6 months. The toxicities analyzed were bowel
frequency/urgency, rectal pain and rectal bleeding. At
each follow-up visit, toxicity events were scored independ-
ently for each of the different toxicity types and the
highest GI toxicity was determined for each patient. Qual-
ity of life (QOL) was assessed via the bowel domain of the
Expanded Prostate Cancer Index (EPIC)-26 questionnaire
prior to treatment and at scheduled follow-up visits after
completion of radiotherapy [27]. The symptoms assessedincluded bowel urgency, bowel frequency, rectal incontin-
ence, rectal bleeding, and rectal pain. As part of our insti-
tutional practice, if patients were unable to return to our
institution for follow-up, QOL questionnaires were mailed
out at the time points where the patient would normally
have been seen, and the clinic notes from their follow-up
visits with local physicians were obtained to assess for
clinical toxicity.
The Wilcoxon signed-rank test was used to compare
follow-up QOL scores to baseline scores. Decreases in the
mean QOL scores at follow-up were considered clinically
Figure 2 Example of multiple non-confluent telangiectasia
(VRS Grade 2) on endoscopy.
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difference (MID), which was defined as ½ of the baseline
standard deviation (SD) [28]. All tests were two-tailed,
and a value of p < 0.05 was considered significant. SAS®
version 9.2 was used to perform the statistical analyses.Results
Overall, we treated 365 patients with SBRT monotherapy
and 120 patients with a SBRT boost and IMRT between
January 2008 and May 2011. Fifty-one of these patients fit
the inclusion criteria for this study, and their characteris-
tics are described in Table 1. The median interval from
completion of SBRT to endoscopy was 13 months. TheFigure 3 Changes in EPIC bowel QOL post-SBRT as a function of time
points at baseline and in follow-up. The numbers represent the number of
½ SD lines represent the clinical minimally important difference.median clinical follow-up was 23 months. Two out of the
51 patients had 2 colonoscopies after SBRT.
A total of 16 (31%) patients reported rectal bleeding
after SBRT, with 12 (24%) patients reporting acute bleed-
ing and 10 patients (20%) reporting late bleeding. The
highest rate of rectal bleeding occurred within 1 month
post radiation treatment with 10 patients admitting to
either Grade 1 or Grade 2 rectal bleeding. Six of these
10 patients experienced complete symptomatic reso-
lution of these acute bleeds by the subsequent follow-up
visit at 3 months. Grade 2 rectal bleeding was observed
by only one patient who required minor cauterization sec-
ondary to a focal area of bleeding telangiectasias. Four of
the 16 patients presenting with rectal bleeding (acute or
late) had evidence of hemorrhoids without telangiectasias
on endoscopy (see below). Overall, Grade 2 acute and late
clinical rectal toxicities were observed in 10 (20%) and 3
(6%) of patients, respectively. The majority of the toxicities
were observed at one specific follow-up appointment and
did not persist on subsequent follow-ups. There were no
Grade 3 or higher acute or late clinical rectal toxicities.
On endoscopy, telangiectasias were found in 10 (20%)
patients: 6 were treated with SBRT monotherapy and 4
where treated with SBRT as a boost. Nine of the 10 pa-
tients were observed to have non-confluent telangiectasias
(VRS Grade 2) (Figure 2), and one was observed to have a
single telangiectasia (VRS Grade 1). No patient had cir-
cumferential telangiectasia. Twelve patients (24%) had evi-
dence of rectal mucositis on endoscopy, 11 patients (22%)
with VRS Grade 1 and 1 patient (2%) with VRS Grade 2.
No patients had a VRS grade for mucositis or telangiecta-
sia of 3 or higher. No rectal ulcerations, strictures, or. Mean EPIC bowel score for all patients reporting at the specified time
patients answering the questionnaire at that time point. The dashed
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bleeding, 3 had evidence of both telangiectasias and mu-
cositis on endoscopy, 1 had telangiectasias without muco-
sitis, and 1 had mucositis without telangiectasias.
Twenty patients (39%) were noted to have hemorrhoids
on endoscopy, although only 1 of these patients had com-
plained of clinical symptoms of hemorrhoids on follow-up.
Three additional patients had clinical symptoms of hemor-
rhoids but had no hemorrhoids seen during the time of
endoscopy.
Mean EPIC bowel scores decreased from a baseline value
of 96.9 to 82.3 at 1-month (p < 0.001). These values subse-
quently improved, but were still lower compared to base-
line values with 90.2 at 12-months (p < 0.001) and 91.0 at
24-months (p = 0.01) post-SBRT. Figure 3 illustrates the
change of EPIC bowel QOL over subsequent follow-up.
Discussion
Stereotactic body radiation therapy (SBRT) offers to min-
imize radiation-associated rectal toxicity by reducing the
volume of rectum receiving high radiation doses. The low
rate of late Grade ≥ 2 rectal toxicity seen in this study is
consistent with the results from a prior review by our in-
stitution [19] and results from other institutions, [20-22]
which all report a rate of late Grade ≥ 2 rectal toxicity of <
10%. The lack of acute or late Grade 3 toxicity in these co-
horts is particularly encouraging. Endoscopy is the gold
standard for assessing rectal mucosal injury following ra-
diation therapy. Our study is the first to examine endo-
scopic outcomes after prostate SBRT.
Since many of the patients in our study had an endoscopy
to evaluate rectal symptoms, the study population is skewed
towards patients who have more rectal complaints. How-
ever, even in this select group of patients, the rate of tel-
angiectasias of 20% is lower than the rate of 32%-88%
reported in prospective studies that have looked at endo-
scopic outcomes after 3D-CRT or IMRT [6,26,29-32]. In
addition, no diffuse/confluent (VRS Grade 3) telangiectasias
were seen in our patients, while a rate of 5%-25% is re-
ported in the other studies. Based on our results and
the results of others, we do not believe that intrarectal
amifostine is necessary during prostate SBRT as others
have reported [20].
In this select patient population, the overall incidence
of post-treatment bleeds is 31%. However, only half of
the patients who had telangiectasia on our study had
symptomatic rectal bleeding. Additionally, 25% of our
patients who reported rectal bleeding had hemorrhoids
without evidence of telangiectasias on endoscopy. Together,
this suggests that there could be alternative causes for the
post-treatment bleeding seen in SBRT-treated patients aside
from late post-radiotherapy telangiectasia. These causes
could potentially include acute anal irritation or exacerba-
tion of hemorrhoids.Despite studying a patient population weighted towards
those with rectal complaints, the pattern seen in the mean
rectal QOL after SBRT in our study is similar to the pat-
tern seen after conventionally fractionated radiotherapy or
brachytherapy. The mean QOL score is at its lowest 1 or
2 months after treatment, but improves slowly thereafter
to near baseline by 1–2 years after treatment.
Our study is limited by the retrospective nature of the
analysis. Another limitation of this study is that the number
of patients is relatively small, hampering our ability to per-
form an analysis of patient-specific and treatment-related
factors that can affect rectal toxicity. In addition, the me-
dian follow up in this group of patients is relatively short,
and additional clinical or endoscopic toxicities could poten-
tially be seen with longer follow up.Conclusions
The treatment of prostate cancer with SBRT delivered
using the CyberKnife system to doses of 35–36.25 Gy in
5 fractions or 19.5 Gy in 3 fractions with 45–50.4 Gy
IMRT has a low rate of Grade > 2 or higher toxicity. No
rectal strictures, fistulas, ulcers, or perforations were ob-
served. Prospective trials examining the endoscopic out-
comes following SBRT for prostate cancer are needed
for confirmation of the findings of this study.Abbreviations
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